Ivermectin and Cancer: What the Science Really Says

Ivermectin has established uses against certain parasitic infections and is being investigated in cancer research. Those are different uses with different evidence requirements. The research reviewed here does not establish an ivermectin cancer treatment that a reader can safely follow at home. [1] [5] [8]

Evidence checked September 10, 2026. This article distinguishes laboratory experiments, an ongoing clinical trial and observational reports. It includes editorial warnings attached to two frequently discussed publications.

What laboratory studies can tell us

A 2014 study by Melotti and colleagues reported that ivermectin affected WNT-TCF signaling in cancer cells and inhibited some WNT-dependent tumors grown in mice. These findings help researchers formulate hypotheses about how a compound might act. They do not show that taking ivermectin treats a person's cancer or identify an effective human cancer dose. [2]

A separate 2021 breast-cancer study reported immune effects and activity with checkpoint blockade in cell and mouse experiments. On June 5, 2026, the journal issued an Editorial Expression of Concern: further image similarities had been identified after a correction, and the original data were unavailable. The notice advises caution in interpreting the data. This article therefore does not present those experiments as reliable proof of clinical benefit. [3] [4]

What is being tested in patients?

ClinicalTrials.gov lists NCT05318469, a study of ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer. Its registered design is an open-label, single-group Phase 1/2 study. The official record checked on September 10, 2026 listed recruitment as ongoing and contained no posted study results; its last update was August 5, 2026. This registry status does not exclude the possibility of separate preliminary conference reports. [5]

A registered trial shows that a question is being investigated. It is not a treatment endorsement. A study of a combination also cannot automatically establish how much benefit, if any, comes from ivermectin itself. Its eligibility criteria and investigator-supervised treatment cannot be converted into a general self-treatment schedule.

How should the 197-patient observational report be interpreted?

A 2026 paper described patients receiving ivermectin and mebendazole through a telemedicine service, using patient-reported outcomes; some participants also received other treatments. It was observational rather than a randomized comparison. Its reported outcomes cannot isolate the effect of either medicine. [6]

On June 9, 2026, Anticancer Research issued an Expression of Concern addressing the dataset's verifiability, statistical reliability and ethical oversight, and announced a review of the underlying records. The notice is part of the publication record and must be considered alongside the original paper. The report should not be presented as a demonstrated response rate for ivermectin cancer treatment. [7]

Approval, dose and safety are separate questions

The U.S. STROMECTOL tablet label lists antiparasitic indications, not cancer. FDA explains that approval for one use does not establish safety and effectiveness for another. There is no cancer dosing recommendation in that label. This article does not supply a cancer dose, pulse schedule or absorption-enhancing regimen. [1] [8]

The label includes clinically relevant warnings and interactions, including reports of increased INR with warfarin. Safety experience from treating parasites should not be used to promise that prolonged or combined oncology use is safe. Do not change a prescribed cancer treatment or add ivermectin on the basis of this article; discuss research questions and medicines with the oncology team. [1] [8]

Questions to bring to an oncology appointment

Is there a registered trial relevant to my cancer type and current treatment?
Does the evidence describe people, animals or cells, and are there editorial warnings?
Could an additional medicine interfere with my current treatment or its monitoring?

Frequently Asked Questions

Does laboratory anticancer activity establish a treatment for people?

No. The cited WNT study used laboratory and mouse models. Human benefit and an acceptable benefit-risk balance require clinical evidence; a cell-culture result cannot provide a personal dose. [2]

Does the registered trial prove ivermectin works for cancer?

No. The checked registry record describes an investigational combination and has no posted results. Registration alone does not establish effectiveness. [5]

Why are the editorial notices included?

They are part of the current publication record. Omitting them would give readers an incomplete picture of the two cited studies and their limitations. [4] [7]

Research questions remain open. The sources below support a cautious discussion of the evidence, not instructions to replace or supplement oncology care without the treating clinician.